GI Dynamics

Category Archives

GI Dynamics, Inc. Appoints David Maggs, M.D. as Chief Medical Officer

LEXINGTON, Massachusetts & SYDNEY – April 30, 2013 – GI Dynamics, Inc. (ASX: GID) today announced the appointment of David Maggs, M.D. to the position Read more...

GI Dynamics, Inc. Reports on Progress of the ENDO Trial

LEXINGTON, Massachusetts & SYDNEY, Australia – 25 April 2013 – GI Dynamics, Inc. (ASX: GID) today announced an update on the status of the ENDO Read more...

EndoBarrier® Therapy Named Product of the Year by BioSpectrum Asia

LEXINGTON, Massachusetts & SYDNEY – 18 March 2013 – GI Dynamics, Inc. (ASX: GID) today announced that EndoBarrier® Therapy, the Company’s non-surgical, Read more...

GI Dynamics Announces Agreement with CMS Medical for Distribution of EndoBarrier® Therapy in Brazil

ANVISA Regulatory Submission Filed LEXINGTON, Massachusetts, SYDNEY, Australia & GOIÂNIA, Brazil – 6 March 2013 – GI Dynamics, Inc. (ASX: GID) Read more...

GI Dynamics Announces Commercial Availability of EndoBarrier® Therapy in Israel for the Treatment of Type 2 Diabetes and/or Obesity

Sheba Medical Center is First to Offer EndoBarrier Therapy in Israel LEXINGTON, Massachusetts & SYDNEY – 26 February 2013 – GI Dynamics, Inc. Read more...

Data Show EndoBarrier® Therapy Demonstrates Glycemic Control in People with Type 2 Diabetes Who are Mildly Obese

-- Results Published in Journal of Clinical Endocrinology & Metabolism Show EndoBarrier Effects in People with Type 2 Diabetes and Lower Body Mass Read more...

GI Dynamics, Inc. Initiates U.S. Pivotal Clinical Trial of EndoBarrier®

LEXINGTON, Mass. & SYDNEY -- Jan. 15, 2013 -- GI Dynamics, Inc. (ASX: GID) today announced that it has initiated its U.S. multicenter pivotal clinical Read more...

GI Dynamics Announces Resolution of Litigation with Gore

Gore Drops All Claims Against GI Dynamics Lexington, Massachusetts, United States and Sydney, Australia – 9 January 2013 – GI Dynamics, Inc. (GI Dynamics Read more...

GI Dynamics Announces Research Collaborations with GlaxoSmithKline and Medtronic

LEXINGTON, Mass., U.S. and SYDNEY, Australia – 4 January 2013 – GI Dynamics, Inc. (ASX: GID) today announced that the company has entered into separate Read more...

GI Dynamics, Inc. Receives FDA Approval to Commence Pivotal Clinical Trial of EndoBarrier®

Results will be used to support a Premarket Application (PMA) for EndoBarrier LEXINGTON, Mass. & SYDNEY --(BUSINESS WIRE)--Oct. 29, 2012-- GI Dynamics, Read more...

Page 1 of 4123...Last »

Contact Info

info@catalysthealthventures.com

(781) 228-5228

50 Braintree Hill Office Park
Suite 301
Braintree, MA 02184